

Specification Amendments

On page 19, line 4, please delete the following Table 1:

**Table 1**

	<b>ORGAN</b>	<b>TUMOR TYPE</b>
1	Ovary	Adenocarcinoma Mucin-
2		Leukemia lymphoid
3	Limb	Angiosarcoma
4	Uterus	Adenocarcinoma
5	Soft Tis-	Sarcoma
6	Ovary	Adenocarcinoma Cystic
7	Rectum	Adenocarcinoma
8	Pelvis	Carcinomatosis
9		Generally Spread Tumor
10	Brain	Astrocytoma
11	Lung	Neoplasia
12	Liver	Primary Hepatoma
13	Pelvis	Neoplasia
14	Kidney	Neoplasia (Metastatic)
15	Colon	Neoplasia
16	Bone	Osteosarcoma

Please replace pages 37-40, which now includes the deletion from page 19 and what was already present on pages 37-40.

**Table 1**

	<b>ORGAN</b>	<b>TUMOR TYPE</b>
<b>1</b>	Ovary	Adenocarcinoma Mucin.
<b>2</b>		Leukemia lymphoid
<b>3</b>	Limb	Agiosarcoma
<b>4</b>	Uterus	Adenocarcinoma
<b>5</b>	Soft Tis.	Sarcoma
<b>6</b>	Ovary	Adenocarcinoma Cystic
<b>7</b>	Rectum	Adenocarcinoma
<b>8</b>	Pelvis	Carcinomatosis
<b>9</b>		Generally Spread Tumor
<b>10</b>	Brain	Astrocytoma
<b>11</b>	Lung	Neoplasia
<b>12</b>	Liver	Primary Hepatoma
<b>13</b>	Pelvis	Neoplasia
<b>14</b>	Kidney	Neoplasia (Metastatic)
<b>15</b>	Colon	Neoplasia
<b>16</b>	Bone	Osteosarcoma

	A	B	C	D	E	F	G
1							
2		TABLE 1					
3							
4		CANCER + PATIENTS					
5							
6	Case #	Name	Sex	LOCALIZATION	FINAL DIAGNOSIS		
7							
8	1	J.G.	F	Soft Tis.	Sarcoma		
9	2	O.R.	M	Bladder	Epithelioma		
10	6	A.B.	F	Ovary	Adenocar Mucin.		
11	10	M.S.	F		Leukemia lymphoid		
12	14	M.B.	F	Limb	Agiosarcoma		
13	15	G.B.	F	Uterus	Adenocarcinoma		
14	18	J.E.	M	Soft Tis.	Sarcoma		
15	19	S.F.	F	Ovary	Adenocarcinoma Cystic		
16	24	E.G.	F	Rectum	Adenocarcinoma		
17	32	M.C.O.	F	Pelvis	Carcinomatosis		
18	33	E.M.	F	Abdomen	Gen. Spread Tumor		
19	34	H.D.G.	F	Brain	Astrocytoma		
20	35	C.B.	M	Lung	Neoplasia		
21	37	R.F.	M	Liver	Primary Hepatoma		
22	67	C.D.	M	Pelvis	Neoplasia		
23	68	C.M.	F	Kidney	Neoplasia (Met)		

24	69	U.D.S.	M	Colon	Neoplasia	
25	41	J.B.	F	Bone	Osteosarcoma	
26						
27						
28						
29		CANCER-PATIENTS				
30						
31	39	H.T.	F	Lung	Vasc. hypoplasia	
32	40	M.L.	F		Vascular disease	
33	58	O.H.	M	Brain	Meningioma	
34	7	S.R.	M	Lymph node	Imflamatory	
35	16	S.C.	M	Liver	Cyrrosis	
36	21	B.P.	M	Prostate	Adenoma	
37	29	M.B.	F	Brain	Meningeal hemorrhage	
38	30	H.A.	M		Vascular disease	
39	44	A.A.	M		Vascular disease	
40	45	J.F.T.	M	Brain	Ischemic accident	
41	46	G.N.	M	Kidney	Malformation	
42	47	H.P.P.	M		Vascular disease	
43	48	M.S.	F		Vascular disease	
44	51	B.O.	F		Vascular disease	
45	53	J.G.	M		Hypertension	
46	54	J.S.	M		Hypertension	
47	55	J.M.	M		Normal	

48	56	A.T.	M		Vascular disease	
49	61	F.D.	M	Brain	Meningeal hemorrhagy	
50	N1	J.L.I.	M		Normal	
51	N2	E.V.	M		Normal	
52	N3	F.F.	M		Normal	

Page 41, insert before first paragraph:

The present invention pertains to a method for treating cancer cells in a patient. The method comprises the steps of introducing labeled antibodies against alphafetoprotein in relation to normal non-malignant individuals into the patient. There is the step of reacting the labeled antibodies against alphafetoprotein with alphafetoprotein receptor of cancer cells from the group consisting of ovary, uterus, rectum, brain, liver, blood, serum and bone of the patient to inhibit growth of the cancer cells or kill the cancer cells.

Preferably, the introducing step includes the step of injecting the labeled antibodies into the patient. The injecting step preferably includes the step of injecting through an IV into the patient's blood stream the labeled antibodies. Preferably, the injecting step includes the step of injecting the labeled antibodies into the patient at a location in proximity to the cancer cells.